2 results
Approved WMOCompleted
- To evaluate the efficacy of pitolisant ( 5, 10, 20,40mg/d in the Double Blind Period and 5, 10, 15, 20, 30, 40mg/d in the Open Label Period) in reducing residual Excessive Daytime Sleepiness (EDS) and the number of cataplectic episodes (for…
Approved WMOCompleted
The main purpose of this study is to investigate the effect of ASTX660 on how quickly and to what extent quinidine and fexofenadine are absorbed, distributed, broken down and eliminated from the body. Quinidine and fexofenadine have been chosen…